10-K · March 19, 2026
Relmada Therapeutics reported no revenue for the fiscal year ended December 31, 2025, resulting in a net loss of approximately $57.4 million. The firm has pivoted away from previous drug candidates like esmethadone and…
Earnings analysis · 10-Q
RLMD earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
Relmada Therapeutics reported a net loss of approximately $19.05 million for Q1 2026, an increase from the $17.56 million loss in Q1 2025. Revenue remains non-existent, indicating a continuation of significant financial…
Read full summary
Relmada Therapeutics reported a net loss of approximately $19.05 million for Q1 2026, an increase from the $17.56 million loss in Q1 2025. Revenue remains non-existent, indicating a continuation of significant financial challenges despite efforts to realign their development strategy and pursue new candidates like NDV-01 and sepranolone.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.22
What stood out
-
Increased Net Loss Year-over-Year
Net loss increased to $19,052,000 in Q1 2026 from $17,559,500 in Q1 2025.
-
Higher Operating Cash Flow Loss
Operating cash flow loss was $15,067,488, an improvement from $18,067,033 in the prior year.
-
Research Expenses Reduction
Research and development expenses decreased from $11,951,023 in Q1 2025 to $8,087,845 in Q1 2026, a drop of $3,863,178.
-
Cash and Investments Increase
The company reported a net increase in cash of $6,279,860 during Q1 2026.
-
Interest Income Growth
Interest/investment income increased to $959,800 from $440,300 year-over-year.
-
Reduction in Short-term Investments Loss
Unrealized losses on investments decreased from $155,700 to $540,100.
What to watch
-
No Revenue Generation Continues
The company has not generated any revenue since inception, continuing to face critical financial challenges.
-
Increased General and Administrative Expenses
General and administrative expenses surged to $11,373,909 from $6,267,412, marking an increase of over $5 million.
-
Significant Operational Losses
The total net loss for the past quarter reached $19,052,000, exemplifying ongoing challenges in maintaining financial viability.
Management's outlook
Management does not expect to generate revenue for the foreseeable future, focusing instead on advancing clinical candidates.
Earlier filings 4
10-Q · November 13, 2025
Relmada Therapeutics reported no revenue for Q3 2025 and a diluted EPS of -0.30, highlighting ongoing financial challenges. Operating expenses decreased significantly compared to the prior year, but the company remains…
10-Q · August 7, 2025
Relmada Therapeutics reported no revenue and a diluted EPS loss of $0.30 for Q2 2025, marking a consistent trend of losses across several quarters. Operating expenses have significantly decreased from the previous year,…
10-Q · May 12, 2025
Relmada Therapeutics, Inc. reported no revenue for Q1 2025 and continued to post significant net losses, driven by high operating expenses, despite a decrease compared to the prior year. Management has shifted focus…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.